Glycosidase

Kifunensine is a potent and selective inhibitor of class I α-mannosidases, originally isolated from *Actinomycete* species. It blocks the trimming of mannose residues from N-linked glycoproteins by inhibiting α-mannosidase I activity, thereby preventing proper glycoprotein maturation. Through this mechanism, Kifunensine disrupts endoplasmic reticulum–associated degradation (ERAD) pathways, leading to the accumulation of misfolded glycoproteins. It is widely used as a biochemical tool in studies of protein folding, quality control, and glycosylation.

M-31850 is a selective and competitive inhibitor of β-hexosaminidase, demonstrating IC50 values of 6.0 μM for human HexA and 3.1 μM for human HexB. This compound also inhibits β-N-acetyl-D-hexosaminidase (OfHex2) with a Ki of 2.5 μM. M-31850 is valuable for research applications focused on lysosomal storage disorders and other biological contexts where β-hexosaminidase activity is implicated.

Deoxyfuconojirimycin hydrochloride is a selective inhibitor of α-L-fucosidase, demonstrating a Ki value of 10 nM for human liver lysosomal α-L-fucosidase and 140 nM for Charonia lampas α-L-fucosidase. This compound effectively inhibits the activity of all soluble α-L-fucosidases present in human liver, including various post-translationally modified enzyme forms. Deoxyfuconojirimycin hydrochloride is primarily utilized in research focused on fucosidase-related enzyme activity and metabolic pathways, though it does not exhibit anti-HIV properties.

AMP-Deoxynojirimycin is a potent inhibitor of glucocerebrosidase 2 (GCase 2) and ceramide glucosyltransferase. This compound effectively interferes with glucosylceramide (GlcCer) biosynthesis, making it valuable for research related to lysosomal storage disorders and sphingolipid metabolism. Its biological activity positions AMP-Deoxynojirimycin as a significant tool for investigating the roles of GlcCer in various cellular processes and disease mechanisms.

Glucobrassicin potassium is a glucosinolate (GSL) that functions as a potent weed inhibitor. Isolated from wild carrot (Raphanus raphanistrum L.), it demonstrates significant potential in biological fumigation and allelopathy research. Its application in weed management studies supports the exploration of sustainable agricultural practices.

Gcase Activator 2 is a pyrrolo[2,3-b]pyrazine that serves as a potent activator of β-glucocerebrosidase (GCase), with an EC50 of 3.8 μM. This compound facilitates GCase dimerization, promoting both K-type and V-type interactions. Gcase Activator 2 displays low metabolic clearance in both human and mouse systems, making it a valuable tool for research into GCase-related biological pathways and potential therapeutic applications in lysosomal storage disorders.

CHI3L1-IN-3 is a potent inhibitor of CHI3L1, with dissociation constants of 13.76 μM and 13.5 μM as measured by MST and SPR assays, respectively. This compound exhibits favorable pharmacokinetic properties, including extended plasma half-lives and microsomal stability, alongside decreased intrinsic clearance. In biological assays, CHI3L1-IN-3 demonstrates dose-dependent cytotoxicity, effectively reduces spheroid mass, and inhibits cell migration in a three-dimensional multicellular glioblastoma (GBM) spheroid model. It serves as a valuable tool for investigating the roles of CHI3L1 in GBM research.

CHI3L1-IN-2 is a selective inhibitor of CHI3L1 (Chitinase-3-Like Protein 1) that targets its interaction with heparan sulfate (CHI3L1:HSIII), exhibiting an IC50 of 26 nM. CHI3L1 is a glycoprotein linked to various pathological conditions including inflammation, fibrosis, and cancer. This compound serves as a valuable tool for researchers investigating the role of CHI3L1 in disease processes and therapeutic applications.

Glucocerebrosidase-IN-1 is a selective inhibitor of glucocerebrosidase (GCase), exhibiting an IC50 of 29.3 μM and a Ki of 18.5 μM. This compound is instrumental in research related to Gaucher disease and Parkinson's disease, allowing for the investigation of GCase's role in these conditions. Its potency and specificity make it a valuable tool for elucidating the biochemical pathways involved in lysosomal storage disorders.

Migalastat is an orally active inhibitor of α-galactosidase A, functioning primarily as a molecular chaperone with an IC50 value of 0.04 μM for human α-Gal A. This compound selectively binds to the active site of specific unstable mutant forms of α-galactosidase A, promoting their proper transport to the lysosome. Upon dissociating in the acidic lysosomal environment, Migalastat enhances the biological activity of the mutant enzyme, making it a valuable tool in research related to lysosomal storage disorders.

(3R,4R)-4-(Hydroxymethyl)pyrrolidin-3-ol functions as a glycosidase inhibitor. This compound demonstrates significant biological activity by modulating the activity of glycosidases, which are crucial in carbohydrate metabolism. It serves as an important intermediate for the synthesis of various biologically active molecules, making it valuable in chemical research and drug development applications.

Terrestrimine is a potent α-Glycosidase inhibitor, demonstrating an IC50 of 225.83 μM. This compound is significant in the study of metabolic disorders, as it can modulate carbohydrate metabolism and glycemic control. It serves as a valuable tool for researchers investigating the role of glycosidase enzymes in various metabolic conditions.

(-)-Adenophorine is a potent glycosidase inhibitor that specifically targets α-L-fucosidase, exhibiting an IC50 of 72 μM. This compound plays a crucial role in biochemical research by facilitating studies on glycoprotein metabolism and cellular signaling pathways. Its ability to modulate glycosidase activity makes it a valuable tool for investigating disease mechanisms and developing therapeutic strategies.

Glucocerebrosidase-IN-2 is a potent inhibitor of glucocerebrosidase, a critical enzyme in lipid metabolism linked to Gaucher disease. This quinazoline derivative enhances glucocerebrosidase translocation to lysosomes in patient-derived cells, particularly those with the N370S mutation. It effectively inhibits the hydrolysis of substrates such as 4-methylumbelliferone β-D-glucopyranoside and fluorescent glycosylceramide in N370S mutant tissues, exhibiting an AC50 of 25.29 μM. Glucocerebrosidase-IN-2 is valuable for research focused on therapeutic approaches for Gaucher disease and related lysosomal storage disorders.

Glycosidase-IN-2 is a potent glycosidase inhibitor classified as an azasugar. This compound exhibits hypoglycemic activity, making it valuable in researching mechanisms related to glucose metabolism and diabetes management. Its ability to modulate glycosidase activity provides insights into carbohydrate processing and potential therapeutic applications for glycemic control.

Glycosidase-IN-3 is a pyrimidine compound that acts as a selective inhibitor of beta-glucocerebrosidase. It has demonstrated significant biological activity relevant to the study of lysosomal storage disorders, particularly Gaucher's disease, as well as neurodegenerative conditions such as Parkinson's disease. This compound is suitable for use in research focused on these diseases and their underlying mechanisms.

Nojirimycin is a nitrogen-containing sugar analog that functions as a glycosidase inhibitor. Its unique structure includes a ring nitrogen atom, which acts as an isostere of the oxygen atom in sugar rings, effectively inhibiting the activity of glycosidases. This compound is valuable in biochemical research for studying enzymatic functions and exploring metabolic pathways involving glycosidases.

α-HNJNAc is a potent, competitive inhibitor of hexosaminidases, selectively targeting these enzymes while demonstrating no interference with other glycosidases. This specificity makes α-HNJNAc an invaluable tool for research applications focused on the modulation of glycan metabolism and the study of lysosomal storage disorders. Its ability to inhibit hexosaminidases can aid in unraveling the biochemical pathways involved in glucosamine metabolism and related enzymatic activities.

CHI3L1-IN-1 is a selective inhibitor of Chitinase-3-like protein 1 (CHI3L1), also known as YKL-40, with an IC50 of 50 nM. This compound exhibits additional effects by inhibiting the hERG channel with an IC50 of 2.3 μM. CHI3L1-IN-1 is valuable for research applications focused on the roles of CHI3L1 in inflammation and cancer, offering insights into its potential as a biomarker and therapeutic target.

OGT-2115 is a heparanase inhibitor with IC50 value of 0.4 μM.